Genenta Science S.p.A. (NASDAQ:GNTA - Get Free Report)'s stock price was up 7% on Tuesday . The company traded as high as $4.46 and last traded at $4.45. Approximately 2,004 shares traded hands during trading, a decline of 86% from the average daily volume of 14,696 shares. The stock had previously closed at $4.16.
Genenta Science Stock Performance
The stock's 50 day moving average is $3.95 and its two-hundred day moving average is $4.31.
Institutional Investors Weigh In On Genenta Science
Institutional investors and hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC acquired a new position in Genenta Science in the 4th quarter valued at about $46,000. Algebris UK Ltd grew its stake in shares of Genenta Science by 122.2% in the 1st quarter. Algebris UK Ltd now owns 100,000 shares of the company's stock valued at $368,000 after purchasing an additional 55,000 shares during the last quarter. Finally, Allianz SE acquired a new position in shares of Genenta Science in the fourth quarter valued at approximately $444,000. 15.13% of the stock is owned by hedge funds and other institutional investors.
Genenta Science Company Profile
(
Get Free Report)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Further Reading
Before you consider Genenta Science, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genenta Science wasn't on the list.
While Genenta Science currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
